Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676
View directory record Official record
Conditions
Acne Vulgaris
Interventions
VB-1953 - 2%, VB-1953 - 0% (Vehicle)
Drug
Lead sponsor
Vyome Therapeutics Inc.
Industry
Eligibility
9 Years to 45 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Ontario, California • Sherman Oaks, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

NCT06415292
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% cream
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health

NCT04884516
View directory record Official record
Conditions
Acne, Adult
Interventions
Retinol gummy
Dietary Supplement
Lead sponsor
Embody Beauty, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

NCT00135733
View directory record Official record
Conditions
Lichen Planus
Interventions
Amevive (Alefacept), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 31, 2026, 11:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin

NCT05941065
View directory record Official record
Conditions
Skin Microboime, Acne
Interventions
Balancing gel cream
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 31, 2026, 11:01 AM EDT
Not listed Not applicable Interventional

NdYag Laser for Acne Keloidalis Nuchae

NCT00757315
View directory record Official record
Conditions
Acne Keloidalis Nuchae, NdYag Laser, AKN, Acne Keloidalis, AK, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Sycosis Nuchae, Acne Keloid, Keloidal Folliculitis, Lichen Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Sycosis Framboesiformis
Interventions
NdYag Laser(hair removal laser) plus topical corticosteroid, Topical corticosteroid alone
Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 31, 2026, 11:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis

NCT05942248
View directory record Official record
Conditions
Acne, Melasma, Rosacea, Seborrheic Dermatitis
Interventions
No Intervention
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 31, 2026, 11:01 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 11:01 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550
View directory record Official record
Conditions
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions
Xolair
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
View directory record Official record
Conditions
Inflammatory Acne
Interventions
LYS006 20 mg, LYS006 2 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

NCT07468175
View directory record Official record
Conditions
Hyperpigmentation, Dark Spots
Interventions
Cosmetic dark spot corrector serum
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

NCT03599193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

NCT07863193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Denifanstat, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

NCT02932267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.3% / BPO 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

NCT03761784
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing OTC Acne Treatment to Prescription Regimen

NCT01237821
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BenzaClin, Effaclar
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

NCT01019603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene, Tazaroc Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 31, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

NCT04993066
View directory record Official record
Conditions
Pseudofolliculitis Barbae, Unwanted Hair, Pigmented Lesions, Vascular Lesion, Onychomycosis, Wrinkle, Acne
Interventions
GentleMax Pro Plus
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 31, 2026, 11:01 AM EDT